172 related articles for article (PubMed ID: 21159570)
1. Rosuvastatin reduces neointima formation in a rat model of balloon injury.
Preusch MR; Vanakaris A; Bea F; Ieronimakis N; Shimizu T; Konstandin M; Morris-Rosenfeld S; Albrecht C; Kranzhöfer A; Katus HA; Blessing E; Kranzhöfer R
Eur J Med Res; 2010 Nov; 15(11):461-7. PubMed ID: 21159570
[TBL] [Abstract][Full Text] [Related]
2. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury.
Kappert K; Leppänen O; Paulsson J; Furuhashi M; Carlsson MA; Heldin CH; Fätkenheuer G; Rosenkranz S; Ostman A
J Acquir Immune Defic Syndr; 2006 Dec; 43(4):383-92. PubMed ID: 16967043
[TBL] [Abstract][Full Text] [Related]
3. Rosuvastatin prevents angiotensin II-induced vascular changes by inhibition of NAD(P)H oxidase and COX-1.
Colucci R; Fornai M; Duranti E; Antonioli L; Rugani I; Aydinoglu F; Ippolito C; Segnani C; Bernardini N; Taddei S; Blandizzi C; Virdis A
Br J Pharmacol; 2013 Jun; 169(3):554-66. PubMed ID: 22817606
[TBL] [Abstract][Full Text] [Related]
4. [Co-overexpression of human tissue kallikrein 1 and human metalloproteinase 1 tissue inhibitor inhibits neointima formation in the rat artery after balloon angioplasty].
Yu HZ; Zhang F; Zhu PL; Pan W; Huang SJ; Xiang H
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 May; 44(5):436-42. PubMed ID: 27220581
[TBL] [Abstract][Full Text] [Related]
5. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury.
Schäfer K; Kaiser K; Konstantinides S
Thromb Haemost; 2005 Jan; 93(1):145-52. PubMed ID: 15630505
[TBL] [Abstract][Full Text] [Related]
6. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
[TBL] [Abstract][Full Text] [Related]
7. Statins and prevention of stent-related late adverse events.
Uemura S
Coron Artery Dis; 2014 Jun; 25(4):277-8. PubMed ID: 24710353
[No Abstract] [Full Text] [Related]
8. The herbal extract HMC05 inhibits neointima formation in balloon-injured rat carotid arteries: possible therapeutic implications of HMC05.
Lee JW; Lee BS; Lee JY; Ku HJ; Jeon SR; Kim JY; Ban JM; Sung SH; Shin HM; Park JE
J Ethnopharmacol; 2011 Jan; 133(1):168-76. PubMed ID: 20883768
[TBL] [Abstract][Full Text] [Related]
9. Effects of Rosuvastatin on Apolipoprotein J in Balloon-Injured Carotid Artery in Rats.
Yang N; Dong B; Yang J; Li Y; Kou L; Liu Y; Qin Q
Arq Bras Cardiol; 2018 Oct; 111(4):562-568. PubMed ID: 30281685
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury.
Bendeck MP; Irvin C; Reidy MA
Circ Res; 1996 Jan; 78(1):38-43. PubMed ID: 8603503
[TBL] [Abstract][Full Text] [Related]
11. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.
Okada Y; Yamaguchi K; Nakajima T; Nishikawa T; Jo M; Mitsumoto Y; Kimura H; Nishimura T; Tochiki N; Yasui K; Mitsuyoshi H; Minami M; Kagawa K; Okanoue T; Itoh Y
Liver Int; 2013 Feb; 33(2):301-11. PubMed ID: 23295058
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Bulhak A; Roy J; Hedin U; Sjöquist PO; Pernow J
Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H3158-63. PubMed ID: 17322412
[TBL] [Abstract][Full Text] [Related]
13. Kinins and the events influenced by an angiotensin-converting enzyme inhibitor during neointima formation in the rat carotid artery.
Farhy RD; Peterson E; Scicli AG
J Hypertens; 1997 Apr; 15(4):421-9. PubMed ID: 9211177
[TBL] [Abstract][Full Text] [Related]
14. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
Crouse JR; Raichlen JS; Riley WA; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Bots ML;
JAMA; 2007 Mar; 297(12):1344-53. PubMed ID: 17384434
[TBL] [Abstract][Full Text] [Related]
15. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.
Li Y; Wang Q; Zhou J; Xu Q; Chu X; Sun T; Liu X; Cai S
Eur J Pharmacol; 2014 Jan; 723():23-8. PubMed ID: 24333476
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin attenuates inflammation, apoptosis and fibrosis in a rat model of cyclosporine-induced nephropathy.
Nam HK; Lee SJ; Kim MH; Rho JH; Son YK; Lee SM; Kim SE; Kim KH; An WS
Am J Nephrol; 2013; 37(1):7-15. PubMed ID: 23258196
[TBL] [Abstract][Full Text] [Related]
18. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Engelhorn T; Doerfler A; Heusch G; Schulz R
Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats.
Hu X; Sun A; Xie X; Huang Z; Jia J; Yao R; Ge J
J Cardiovasc Pharmacol Ther; 2013 Mar; 18(2):162-76. PubMed ID: 23139358
[TBL] [Abstract][Full Text] [Related]
20. Effect of rosuvastatin on the echolucency of the common carotid intima-media in low-risk individuals: the METEOR trial.
Lind L; Peters SA; den Ruijter HM; Palmer MK; Grobbee DE; Crouse JR; O'Leary DH; Evans GW; Raichlen JS; Bots ML;
J Am Soc Echocardiogr; 2012 Oct; 25(10):1120-1127.e1. PubMed ID: 22884641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
